AKOYA BIOSCIENCES INC (AKYA)

US00974H1041 - Common Stock

2.49  -0.06 (-2.35%)

After market: 2.4898 0 (-0.01%)

AKOYA BIOSCIENCES INC

NASDAQ:AKYA (12/20/2024, 8:00:00 PM)

After market: 2.4898 0 (-0.01%)

2.49

-0.06 (-2.35%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS SubIndustryLife Sciences Tools & Services
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%19.23%
Sales Q2Q%-25.12%
CRS10.21
6 Month5.51%
Overview
Earnings (Last)11-14 2024-11-14/amc
Earnings (Next)N/A N/A
Ins Owners4.04%
Inst Owners31.53%
Market Cap123.40M
Shares49.56M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts75.71
Short Float %5.84%
Short Ratio6.03
IPO04-16 2021-04-16
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

AKYA Daily chart

Company Profile

Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company is headquartered in Marlborough, Massachusetts and currently employs 330 full-time employees. The company went IPO on 2021-04-16. The company offers single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. The company offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded (FFPE) tissue sections, and tissue microarrays (TMAs).

Company Info

AKOYA BIOSCIENCES INC

100 Campus Drive, 6th Floor

Marlborough MASSACHUSETTS

P: 18558968401

CEO: Brian McKelligon

Employees: 330

Website: https://www.akoyabio.com/

AKYA News

News Image13 days ago - Akoya Biosciences, Inc.Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of disease recurrence in early-stage melanoma patients to better guide treatment decisions and potentially increase access to life saving therapies for those patients at high risk of developing metastatic disease

News Image13 days ago - Akoya Biosciences, Inc.Akoya Biosciences and NeraCare Enter into an Exclusive Global License Agreement for the Development and Commercialization of the Immunoprint Test for Early-Stage Melanoma Patient Treatment Decisions

Akoya expands clinical test menu, exclusively licensing the global rights to develop and commercialize NeraCare's Immunoprint test for prognostication of...

News Image14 days ago - Akoya Biosciences, Inc.Nature Methods Names Spatial Proteomics "Method of the Year 2024" — Akoya Biosciences Celebrates Industry Milestone
News Image21 days ago - USA News GroupBiotech Advances Drive Cancer Research as Global Rates Continue Upward Trend

/PRNewswire/ -- USA News Group News Commentary – Despite death rates for some cancers being on the decline, there is a global surge in cancer cases among...

News Imagea month ago - Akoya Biosciences, Inc.Akoya Biosciences Reports Third Quarter 2024 Financial Results
News Imagea month ago - Akoya Biosciences, Inc.Akoya Biosciences Reports Third Quarter 2024 Financial Results

MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced its...

AKYA Twits

Here you can normally see the latest stock twits on AKYA, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example